ofloxacin has been researched along with clofazimine in 43 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.33) | 18.7374 |
1990's | 14 (32.56) | 18.2507 |
2000's | 12 (27.91) | 29.6817 |
2010's | 14 (32.56) | 24.3611 |
2020's | 2 (4.65) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Cai, G; Cho, S; Franzblau, SG; Jaki, BU; Lee, IA; McAlpine, JB; Napolitano, JG; Pauli, GF; Suh, JW; Wang, Y; Yang, SH | 1 |
Dufková, I; Hrabálek, A; Karabanovich, G; Klimešová, V; Němeček, J; Pávek, P; Roh, J; Smutný, T; Stolaříková, J; Vávrová, K; Vejsová, M; Vicherek, P | 1 |
Centárová, I; Cole, ST; Čonka, P; Hrabálek, A; Karabanovich, G; Klimešová, V; Mikušová, K; Němeček, J; Pávek, P; Pávková, I; Roh, J; Šarkan, M; Smutný, T; Stolaříková, J; Székely, R; Vávrová, K; Vejsová, M; Vocat, A; Zemanová, J | 1 |
Carazo, A; Hrabálek, A; Karabanovich, G; Klimešová, V; Konečná, K; Němeček, J; Pávek, P; Pavliš, O; Roh, J; Stolaříková, J; Valášková, L; Vávrová, K | 1 |
Carazo, A; Hrabálek, A; Karabanovich, G; Klimešová, V; Němeček, J; Pávek, P; Pavliš, O; Roh, J; Stolaříková, J; Sychra, P; Valášková, L; Vávrová, K; Vlčková, H | 1 |
Bera, S; Mondal, D | 1 |
Dušek, J; Hrabálek, A; Huszár, S; Jand'ourek, O; Karabanovich, G; Klimešová, V; Kočová Vlčková, H; Konečná, K; Konyariková, Z; Korábečný, J; Korduláková, J; Kučera, T; Mikušová, K; Pávek, P; Pávková, I; Pavliš, O; Roh, J; Savková, K; Stolaříková, J; Vávrová, K | 1 |
Jidoi, J; Saito, H; Tomioka, H; Yamada, Y | 1 |
Dekio, S; Hidaka, T; Kawahara, S; Saito, H; Sato, K; Tomioka, H | 1 |
Gao, XX; Li, JR; Zheng, YC; Zhou, JH | 1 |
Grosset, JH; Ji, B; N'Deli, L; Perani, EG; Petinom, C | 1 |
Bryskier, A; Goh, KS; Rastogi, N | 1 |
Bhagat, R; Panchal, N; Shah, A | 1 |
Bryskier, A; Devallois, A; Goh, KS; Rastogi, N | 1 |
Ramachandran, A; Rao, PS; Ravi, S; Sekar, B; Subramanian, M | 1 |
Maw, WW; Saito, H; Sato, K; Tomioka, H | 1 |
Goto, M; Kitajima, S; Miyagi, S; Takizawa, H | 1 |
Arra, GS; Arutla, S; Krishna, DR; Prabhakar, CM | 1 |
Abalos, RM; dela Cruz, EC; Fajardo, TT; Veerasubramanian, P; Villahermosa, LG; Walsh, DS; Walsh, GP | 1 |
Bulchand, HO; Ganapati, R; Pai, VV; Revankar, CR | 1 |
Grillone, S; Pattyn, S | 2 |
Chauhan, DS; Gupta, UD; Katoch, K; Katoch, VM; Natrajan, M; Sharma, RK; Sharma, VD; Singh, D; Singh, HB; Srivastava, K | 1 |
Kashiwabara, Y; Matsuoka, M; Namisato, M | 1 |
Abalos, RM; Balagon, MV; Cellona, RV; Dela Cruz, EC; Fajardo, TT; Tan, EV; Villahermosa, LG; Walsh, DS; Walsh, GP | 1 |
Janulionis, E; Sofer, C; Song, HY; Wallis, RS | 1 |
Biswas, SK | 1 |
Gidoh, M; Matsuoka, M; Yamazaki, T | 1 |
Ishikawa, M; Ozaki, M | 1 |
Arenas, R; Asz-Sigall, D; López-García, L; Neme-Yunes, Y; Vega-Memije, ME; Yuen-Palos, R | 1 |
Arunagiri, K; Kumar, BN; Menaka, K; Narayanan, S; Oommen, PK; Sekar, B | 1 |
Hassan, G; Kant, S; Parengal, J; Saheer, S | 1 |
Cunha, Mda G; Lockwood, DN | 1 |
Avelleira, JC; Campos, AA; Cruz, RC; Cunha, Mda G; Filho, B; Ghuidella, C; Schettini, AP; Ura, S; Viana, Fdos R; Virmond, M | 1 |
Dogra, S; Narang, T; Sakia, UN | 1 |
Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM | 1 |
Ahuja, M; Darlong, J; Kumar, A; Lavania, M; Nathan, R; Pathak, VK; Sengupta, U; Singh, I; Turankar, RP | 1 |
Ahumada-Topete, VH; Charli-Joseph, Y; Fernández-Sánchez, M; Flores-Suárez, LF; Rodríguez, M | 1 |
3 review(s) available for ofloxacin and clofazimine
Article | Year |
---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
[Survey of new antitubercular agents].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Clofazimine; Humans; Ofloxacin; Rifabutin | 1993 |
[Chemotherapy of Hansen's disease in Japan--present status].
Topics: Anti-Infective Agents; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Japan; Leprostatic Agents; Leprosy; Ofloxacin | 1998 |
5 trial(s) available for ofloxacin and clofazimine
Article | Year |
---|---|
Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy.
Topics: Adolescent; Adult; Animals; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Foot; Humans; Leprosy, Lepromatous; Male; Mice; Microbial Sensitivity Tests; Middle Aged; Mycobacterium leprae; Ofloxacin; Skin | 1994 |
Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy.
Topics: Adult; Animals; Anti-Infective Agents; Biopsy, Needle; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Mice; Ofloxacin; Treatment Outcome | 1994 |
A 6 week quadruple drug regimen for the treatment of multibacillary leprosy.
Topics: Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leprostatic Agents; Leprosy; Male; Minocycline; Mycobacterium leprae; Ofloxacin; Rifampin; Treatment Outcome | 2000 |
Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Topics: Adolescent; Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Leprosy; Male; Middle Aged; Minocycline; Ofloxacin; Rifampin | 2004 |
OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Topics: Adolescent; Adult; Animals; Brazil; Clofazimine; Dapsone; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leprostatic Agents; Leprosy, Multibacillary; Male; Mice; Middle Aged; Mycobacterium leprae; Ofloxacin; Prevalence; Rifampin; Secondary Prevention; Skin; Time Factors; Treatment Outcome; World Health Organization; Young Adult | 2012 |
35 other study(ies) available for ofloxacin and clofazimine
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular; Peptides, Cyclic; Streptomyces; Vero Cells | 2013 |
1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; HeLa Cells; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitrobenzenes; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2014 |
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacteria; Cell Line; Cell Survival; Drug Design; Drug Resistance, Multiple, Bacterial; Fungi; Humans; Latent Tuberculosis; Microbial Sensitivity Tests; Microsomes; Mutagens; Mycobacterium tuberculosis; Oxazoles; Primary Cell Culture; Rifampin; Structure-Activity Relationship; Thiadiazoles | 2016 |
S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.
Topics: Antifungal Agents; Antitubercular Agents; Drug Design; Drug Resistance; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Oxadiazoles; Structure-Activity Relationship; Sulfhydryl Compounds; Tetrazoles | 2017 |
Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.
Topics: Antitubercular Agents; Caco-2 Cells; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Oxadiazoles; Solubility; Structure-Activity Relationship; Tetrazoles; Water | 2017 |
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
Topics: Alcohol Oxidoreductases; Antitubercular Agents; Bacterial Proteins; Dinitrobenzenes; Dose-Response Relationship, Drug; Drug Development; Hydrocarbons, Fluorinated; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles | 2019 |
Susceptibilities of Mycobacterium leprae and M. avium complex to the H2O2-Fe-mediated halogenation system supplemented with antimicrobial agents.
Topics: Animals; Clofazimine; Dapsone; Ethidium; Ferrous Compounds; Fluoresceins; Humans; Hydrogen Peroxide; Iodides; Mice; Mycobacterium avium Complex; Mycobacterium leprae; Ofloxacin; Rifampin; Sodium Iodide; Staining and Labeling | 1989 |
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rifamycins; Streptomycin | 1995 |
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
Topics: Amikacin; Clofazimine; Drug Synergism; Ethambutol; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Ofloxacin; Rifampin; Roxithromycin | 1994 |
Resistant tuberculosis: successful treatment with amikacin, ofloxacin, clofazimine, and pas.
Topics: Adult; Amikacin; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Male; Ofloxacin; Tuberculosis, Pulmonary | 1993 |
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Clofazimine; Drug Combinations; Ethambutol; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium avium Complex; Ofloxacin; Rifampin; Roxithromycin | 1996 |
Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic
Topics: Adoptive Transfer; Animals; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Immunologic Factors; Interferon-gamma; Leprostatic Agents; Leprosy; Mice; Mice, Inbred BALB C; Mice, Nude; Ofloxacin; Rifamycins | 1997 |
[New WHO recommendations for the treatment of leprosy].
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocycline; Mycobacterium leprae; Ofloxacin; Rifampin; Skin | 1997 |
Pro- and anti-oxidant effects of some antileprotic drugs in vitro and their influence on super oxide dismutase activity.
Topics: Antioxidants; Clofazimine; Dapsone; Dianisidine; Leprostatic Agents; Ofloxacin; Reactive Oxygen Species; Riboflavin; Rifampin; Superoxide Dismutase; Superoxides | 1998 |
Resolution of lepromatous leprosy after a short course of amoxicillin/clavulanic acid, followed by ofloxacin and clofazimine.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clavulanic Acid; Clofazimine; Drug Therapy, Combination; Female; Humans; Leprosy, Lepromatous; Mycobacterium leprae; Ofloxacin; Skin; Treatment Outcome | 1999 |
Single-dose treatment for paucibacillary leprosy; clinical problems and management.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Child; Clofazimine; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocycline; Mycobacterium leprae; Ofloxacin; Prednisolone; Rifampin; Secondary Prevention | 1999 |
Effect of treatment on PCR positivity in multibacillary leprosy patients treated with conventional and newer drugs ofloxacin and minocycline.
Topics: Adenosine Triphosphate; Biopsy; Clofazimine; Dapsone; DNA, Bacterial; Drug Evaluation; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocycline; Mycobacterium leprae; Ofloxacin; Polymerase Chain Reaction; Rifampin; Sensitivity and Specificity; Treatment Outcome | 1999 |
A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Colony Count, Microbial; Dapsone; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Leprostatic Agents; Leprosy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mycobacterium leprae; Ofloxacin; Rifampin | 2000 |
Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
Topics: Belgium; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Leprostatic Agents; Leprosy; Ofloxacin; Recurrence; Rifampin | 2002 |
Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture.
Topics: Anti-Infective Agents; Antitubercular Agents; Area Under Curve; Blood; Cells, Cultured; Clofazimine; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Serum Bactericidal Test | 2004 |
Chemotherapy of leprosy.
Topics: Anti-Bacterial Agents; Clofazimine; Dapsone; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Hypersensitivity; India; Leprosy; Minocycline; Nausea; Ofloxacin; Rifampin; Secondary Prevention; Tuberculosis; World Health Organization | 2004 |
[Basic evaluation for new antimicrobial susceptibility testing of Mycobacterium leprae by bioluminescence assay (ATP method)].
Topics: Animals; Clarithromycin; Clofazimine; Drug Resistance, Bacterial; Leprostatic Agents; Leprosy; Luciferases; Luminescent Agents; Mice; Mice, Nude; Microbial Sensitivity Tests; Mycobacterium leprae; Ofloxacin; Rifampin | 2006 |
[Long-term follow-up of ofloxacin-combined therapy for leprosy patients].
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Cystamine; Drug Therapy, Combination; Follow-Up Studies; Humans; Leprostatic Agents; Leprosy; Male; Middle Aged; Minocycline; Ofloxacin; Rifampin; Time Factors; Treatment Outcome | 2007 |
Type I reaction in a borderline leprosy case successfully treated with multidrug therapy and ofloxacin.
Topics: Anti-Bacterial Agents; Clofazimine; Dapsone; Drug Therapy, Combination; Glucocorticoids; Humans; Leprostatic Agents; Leprosy, Borderline; Male; Middle Aged; Ofloxacin; Prednisone; Rifampin | 2008 |
Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy.
Topics: Animals; Bacterial Proteins; Biopsy; Clofazimine; Cross-Sectional Studies; Dapsone; Dihydropteroate Synthase; DNA Gyrase; Drug Resistance, Bacterial; Genetic Predisposition to Disease; Humans; Leprostatic Agents; Leprosy; Mice; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae; Ofloxacin; Polymerase Chain Reaction; Rifampin | 2011 |
Extra-pulmonary primary multidrug-resistant tubercular lymphadenitis in an HIV negative patient.
Topics: Adult; Antitubercular Agents; Clarithromycin; Clofazimine; Cycloserine; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Ethionamide; Female; HIV Seronegativity; Humans; Isoniazid; Kanamycin; Ofloxacin; Pyrazinamide; Rifampin; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant | 2012 |
Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Topics: Clofazimine; Dapsone; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Minocycline; Mycobacterium leprae; Ofloxacin; Patient Compliance; Rifampin; World Health Organization | 2012 |
Persistent serpentine supravenous hyperpigmented eruption in lepromatous leprosy after minocycline.
Topics: Adult; Anti-Bacterial Agents; Clofazimine; Humans; Hyperpigmentation; Leprostatic Agents; Leprosy, Lepromatous; Male; Minocycline; Ofloxacin | 2015 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
Analysis of bacteriological Index between fixed multidrug therapy and new WHO recommended alternative regimen with ofloxacin, minocycline and clofazimine of rifampicin resistant cases from the hospitals of The Leprosy Mission, India.
Topics: Clofazimine; Drug Therapy, Combination; Hospitals; Humans; India; Leprostatic Agents; Leprosy; Minocycline; Ofloxacin; Rifampin; World Health Organization | 2020 |
After all, still a magnificent impersonator.
Topics: Adult; Biopsy; Clofazimine; Diagnostic Errors; Female; Humans; Leprostatic Agents; Mycobacterium; Mycobacterium Infections, Nontuberculous; Ofloxacin; Peripheral Nervous System Diseases; Rifampin; Skin; Vasculitis | 2021 |